Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,216 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry.
Darmon A, Bhatt DL, Elbez Y, Aboyans V, Anand S, Bosch J, Branch KR, Connolly SJ, Dyal L, Eikelboom JW, Fox KAA, Keltai K, Probstfield J, Yusuf S, Abtan J, Sorbets E, Eagle KA, Ducrocq G, Steg PG. Darmon A, et al. Among authors: steg pg. Eur Heart J. 2018 Mar 1;39(9):750-757a. doi: 10.1093/eurheartj/ehx658. Eur Heart J. 2018. PMID: 29186454
Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE).
Budaj A, Brieger D, Steg PG, Goodman SG, Dabbous OH, Fox KA, Avezum A, Cannon CP, Mazurek T, Flather MD, Van De Werf F; GRACE Investigators. Budaj A, et al. Among authors: steg pg. Am Heart J. 2003 Dec;146(6):999-1006. doi: 10.1016/S0002-8703(03)00509-X. Am Heart J. 2003. PMID: 14660991
Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial.
Mehta SR, Steg PG, Granger CB, Bassand JP, Faxon DP, Weitz JI, Afzal R, Rush B, Peters RJ, Natarajan MK, Velianou JL, Goodhart DM, Labinaz M, Tanguay JF, Fox KA, Yusuf S; ASPIRE Investigators. Mehta SR, et al. Among authors: steg pg. Circulation. 2005 Mar 22;111(11):1390-7. doi: 10.1161/01.CIR.0000158485.70761.67. Circulation. 2005. PMID: 15781750 Clinical Trial.
Medication performance measures and mortality following acute coronary syndromes.
Granger CB, Steg PG, Peterson E, López-Sendón J, Van de Werf F, Kline-Rogers E, Allegrone J, Dabbous OH, Klein W, Fox KA, Eagle KA; GRACE Investigators. Granger CB, et al. Among authors: steg pg. Am J Med. 2005 Aug;118(8):858-65. doi: 10.1016/j.amjmed.2005.01.070. Am J Med. 2005. PMID: 16084178
The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: lessons from the Global Registry of Acute Coronary Events (GRACE).
Goodman SG, Steg PG, Eagle KA, Fox KA, López-Sendón J, Montalescot G, Budaj A, Kennelly BM, Gore JM, Allegrone J, Granger CB, Gurfinkel EP; GRACE Investigators. Goodman SG, et al. Among authors: steg pg. Am Heart J. 2006 Mar;151(3):654-60. doi: 10.1016/j.ahj.2005.05.014. Am Heart J. 2006. PMID: 16504627
Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
Fox K, Ferrari R, Tendera M, Steg PG, Ford I; BEAUTIFUL Steering Committee. Fox K, et al. Among authors: steg pg. Am Heart J. 2006 Nov;152(5):860-6. doi: 10.1016/j.ahj.2006.01.013. Am Heart J. 2006. PMID: 17070146
1,216 results